Foghorn Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Foghorn Therapeutics generated cash of -$118,106,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,778,000 last year. Net change in cash is therefore $28,122,000.
Cash Flow
| 2018 | -22.64M | -1.54M | 51.77M |
|---|---|---|---|
| 2019 | -46.33M | -964K | 23.96M |
| 2020 | -31.28M | -108.91M | 217.47M |
| 2021 | -50.25M | 36.17M | 22.41M |
| 2022 | 193.61M | -244.32M | 1.76M |
| 2023 | -118.10M | 144.45M | 1.77M |
FHTX Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 53.92M | 102.86M | 94.52M | 17.25M | 40.58M | 13.00M |
Operating activities | ||||||
Net income | -98.42M | -108.88M | -101.32M | -68.8M | -51.12M | -26.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 3.45M | 3.32M | 3.22M | 1.32M | 693K | 379K |
Stock-based compensation expense | 16.18M | 14.33M | 8.38M | 2.96M | 1.69M | 0 |
| Deferred income tax benefit | 16.18M | 14.33M | 8.38M | 2.96M | 1.69M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 300M | -300M | 0 | 0 | 0 |
Inventories | 0 | 0 | -3.17M | 0 | 0 | 0 |
Accounts payable | 846K | 1.61M | 135K | 474K | 1.21M | 1.27M |
Cash generated by operating activities | -118.10M | 193.61M | -50.25M | -31.28M | -46.33M | -22.64M |
Investing activities | ||||||
Purchases Of Investments | -73.90M | -409.34M | -99.98M | -92.98M | 0 | 0 |
Investments In Property Plant And Equipment | -1.22M | -1.21M | -3.31M | -16.18M | -968K | -1.54M |
Acquisitions Net | 0 | 243.11M | -39.48M | 250K | 4K | 0 |
Cash generated by investing activities | 144.45M | -244.32M | 36.17M | -108.91M | -964K | -1.54M |
Financing activities | ||||||
Common Stock Issued | 1.77M | 1.76M | 42.20M | 122.12M | 15.98M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -21.20M | -15.53M | 7.98M | -823K |
Cash used in financing activities | 1.77M | 1.76M | 22.41M | 217.47M | 23.96M | 51.77M |
Net Change In Cash | 28.12M | -48.94M | 8.34M | 77.27M | -23.33M | 27.58M |
Cash at end of period | 82.04M | 53.92M | 102.86M | 94.52M | 17.25M | 40.58M |
| Data source | Data source | Data source | Data source |